K
v
ire
.com
←
Back
Night
Docs
Library
Critique
…
Author
Pier Luigi Zinzani
also known as Carolina Terragna, Dennis Weisenburger, P L Zinzani
Istituto di Ematologia di Bologna · Azienda USL di Bologna · University of Bologna · Université Claude Bernard Lyon 1
About this author
Works
1,830
Cited by
61,505
h-index
117
i10
647
ORCID ↗
Top papers
CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group
Michael Pfreundschuh, Lorenz Trümper, Anders Österborg, et al.
·
2006
·
The Lancet Oncology
↗ 2,079
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
Michael Hallek, Kirsten Fischer, Guenter Fingerle-Rowson, et al.
·
2010
·
The Lancet
↗ 1,863
Bortezomib plus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 Trial.
B Coiffier, E.A. Osmanov, Xin Hong, et al.
·
2011
·
The Lancet Oncology
↗ 1,623
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
Elı́as Campo, Elaine S. Jaffe, James R. Cook, et al.
·
2022
·
Blood
↗ 1,436
OA
PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
Ajay K. Gopal, Brad S. Kahl, Sven de Vos, et al.
·
2014
·
New England Journal of Medicine
↗ 1,058
OA
Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma
Robert Chen, Pier Luigi Zinzani, Michelle A. Fanale, et al.
·
2017
·
Journal of Clinical Oncology
↗ 974
OA
Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial
Anas Younes, Armando Santoro, Margaret A. Shipp, et al.
·
2016
·
The Lancet Oncology
↗ 918
OA
CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group
Michael Pfreundschuh, Evelyn Kuhnt, Lorenz Trümper, et al.
·
2011
·
The Lancet Oncology
↗ 806
Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma
Joseph M. Connors, Wojciech Jurczak, David J. Straus, et al.
·
2017
·
New England Journal of Medicine
↗ 753
OA
Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial
Philippe Armand, Andreas Engert, Anas Younes, et al.
·
2018
·
Journal of Clinical Oncology
↗ 744
OA
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial
Steven M. Horwitz, Owen A. O’Connor, Barbara Pro, et al.
·
2018
·
The Lancet
↗ 717
OA
Myeloid sarcoma: clinico-pathologic, phenotypic and cytogenetic analysis of 92 adult patients
Stefano Pileri, Stefano Ascani, Maria Christina Cox, et al.
·
2006
·
Leukemia
↗ 703